REFERENCES
1. Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301-19.
2. Guidi L, Etessami J, Valenza C, et al. Bispecific antibodies in hematologic and solid tumors: current landscape and therapeutic advances. Am Soc Clin Oncol Educ Book. 2025;45:e473148.
3. Gu Y, Zhao Q. Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors. Mol Diagn Ther. 2024;28:669-702.
4. Shim H. Bispecific Antibodies and antibody-drug conjugates for cancer therapy: technological considerations. Biomolecules. 2020;10:360.
5. Iwasaki YW, Tharakaraman K, Subramanian V, et al. Generation of bispecific antibodies by structure-guided redesign of IgG constant regions. Front Immunol. 2022;13:1063002.
6. Madsen AV, Pedersen LE, Kristensen P, Goletz S. Design and engineering of bispecific antibodies: insights and practical considerations. Front Bioeng Biotechnol. 2024;12:1352014.
7. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res. 2008;14:2171-9.
8. Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60:1421-34.
9. Bhatnagar S, Deschenes E, Liao J, Cilliers C, Thurber GM. Multichannel imaging to quantify four classes of pharmacokinetic distribution in tumors. J Pharm Sci. 2014;103:3276-86.
10. Rhoden JJ, Wittrup KD. Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J Pharm Sci. 2012;101:860-7.
11. Yu Y, Feng L, Liu Z. Nanomedicine sheds new light on cancer immunotherapy. Med Rev (2021). 2023;3:188-92.
12. Park JA, Wang L, Cheung NV. Modulating tumor infiltrating myeloid cells to enhance bispecific antibody-driven T cell infiltration and anti-tumor response. J Hematol Oncol. 2021;14:142.
13. Zhou S, Li F, Niu M, Wu K, Li T, Yi M. Advances in the clinical application of bispecific antibodies in cancer therapy. iScience. 2025;28:114203.
14. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101-24.
15. Li J, Yu X, Shi X, Shen M. Cancer nanomedicine based on polyethylenimine-mediated multifunctional nanosystems. Prog Mater Sci. 2022;124:100871.
16. Wu JLY, Ji Q, Blackadar C, et al. The pathways for nanoparticle transport across tumour endothelium. Nat Nanotechnol. 2025;20:672-82.
17. Wang B, Hu S, Teng Y, et al. Current advance of nanotechnology in diagnosis and treatment for malignant tumors. Signal Transduct Target Ther. 2024;9:200.
18. Anaki A, Tzror-Azankot C, Motiei M, Sadan T, Popovtzer R. Impact of synthesis methods on the functionality of antibody-conjugated gold nanoparticles for targeted therapy. Nanoscale Adv. 2024;6:5420-9.
19. Saha T, Fojtů M, Nagar AV, et al. Antibody nanoparticle conjugate-based targeted immunotherapy for non-small cell lung cancer. Sci Adv. 2024;10:eadi2046.
20. Zhang P, Rashidi A, Zhao J, et al. STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma. Nat Commun. 2023;14:1610.
21. Reuveni T, Motiei M, Romman Z, Popovtzer A, Popovtzer R. Targeted gold nanoparticles enable molecular CT imaging of cancer: an in vivo study. Int J Nanomedicine. 2011;6:2859-64.
22. Dreifuss T, Betzer O, Shilo M, Popovtzer A, Motiei M, Popovtzer R. A challenge for theranostics: is the optimal particle for therapy also optimal for diagnostics? Nanoscale. 2015;7:15175-84.
23. Bouché M, Hsu JC, Dong YC, Kim J, Taing K, Cormode DP. Recent advances in molecular imaging with gold nanoparticles. Bioconjug Chem. 2020;31:303-14.
24. Gao Q, Zhang J, Gao J, Zhang Z, Zhu H, Wang D. Gold Nanoparticles in Cancer Theranostics. Front Bioeng Biotechnol. 2021;9:647905.
25. Meir R, Popovtzer R. Cell tracking using gold nanoparticles and computed tomography imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018:10.
26. Betzer O, Perets N, Angel A, et al. In vivo neuroimaging of exosomes using gold nanoparticles. ACS Nano. 2017;11:10883-93.
27. Meir R, Shamalov K, Sadan T, et al. Fast image-guided stratification using anti-programmed death ligand 1 gold nanoparticles for cancer immunotherapy. ACS Nano. 2017;11:11127-34.
28. Xi D, Dong S, Meng X, Lu Q, Meng L, Ye J. Gold nanoparticles as computerized tomography (CT) contrast agents. RSC Adv. 2012;2:12515.
29. Liu X, Fang Y, Li Y, Li Y, Qi L, Wang X. Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials. Front Oncol. 2022;12:894861.
30. Chen W, Yang L, Zhang J, Yuan Y. Efficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs. Syst Rev. 2026;15:45.
31. Jagosky M, Tan AR. Combination of pertuzumab and trastuzumab in the treatment of HER2-positive early breast cancer: a review of the emerging clinical data. Breast Cancer (Dove Med Press). 2021;13:393-407.
32. Wang X, Lee KS, Zeng X, et al. Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study. ESMO Open. 2025;10:105852.
33. Ma J, Wang J, Xu T, et al. Efficacy and safety of KN026 and docetaxel for HER2-positive breast cancer: a phase II clinical trial. Cancer Commun (Lond). 2025;45:476-85.
34. Liu X, Fan X, Gao X, Hu W, Sun P. Leveraging HER2-targeted biparatopic antibodies in solid tumors. Pharmacol Res. 2025;214:107687.
35. Zhang Q, Zhao W, Wang J, et al. Efficacy and safety results of TQB2930, a HER2-targeted bispecific antibody combined with chemotherapy in patients with HER2-positive breast cancer (BC) previously treated with ≥ 2 line treatments: results from a phase 1b/2 study. JCO. 2025;43:1033-1033.
37. Ma T, Sun X, Cui L, et al. Molecular imaging reveals trastuzumab-induced epidermal growth factor receptor downregulation in vivo. J Nucl Med. 2014;55:1002-7.
38. Björkelund H, Gedda L, Barta P, Malmqvist M, Andersson K. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with 125I-EGF. PLoS One. 2011;6:e24739.
39. Maass KF, Kulkarni C, Betts AM, Wittrup KD. Determination of cellular processing rates for a trastuzumab-maytansinoid antibody-drug conjugate (ADC) highlights key parameters for ADC design. AAPS J. 2016;18:635-46.
40. Major M, Nervig CS, Gerland A, Owen SC. Surface-available HER2 levels alone are not indicative of cell response to HER2-targeted antibody-drug conjugate therapies. Pharmaceutics. 2024;16:752.
41. Quimby FW, Luong RH. Clinical chemistry of the laboratory mouse. In: The Mouse in Biomedical Research (Second Edition); Academic Press, 2006; pp 171-216.
42. Patel S, Patel S, Kotadiya A, et al. Comparative analysis of the effect of sex and age on the hematological and biochemical profile of BALB/c and C57BL/6 inbred mice. J Am Assoc Lab Anim Sci. 2025;64:132-45.
43. Lim K, Zhu XS, Zhou D, Ren S, Phipps A. Clinical pharmacology strategies for bispecific antibody development: learnings from FDA-approved bispecific antibodies in oncology. Clin Pharmacol Ther. 2024;116:315-27.
44. Yamamoto Y. Overcoming trastuzumab-pertuzumab resistance and optimizing sequential anti-HER2 therapy in HER2-positive metastatic breast cancer. Cancers (Basel). 2026;18:932.
45. Drittone D, Lucci C, Esposito L, Mazzuca F, Pisegna S. Impact of anti-HER2 therapies on overall survival in patients with HER2-positive metastatic breast cancer: focusing on intracranial efficacy of emerging treatments. Cancers (Basel). 2025;17:3520.
46. Wang R, Jiang S, Zhang Q, Li J. The conditional promise of dual-epitope HER2 antibody-drug conjugates in breast cancer. Cancer Biol Med. ;2026:1-8.
47. Herrera M, Pretelli G, Desai J, et al. Bispecific antibodies: advancing precision oncology. Trends Cancer. 2024;10:893-919.
48. Duwa R, Choi J, Shrestha P, et al. Strengthened binding affinity of bispecific antibody nanoplatforms improved the anti-tumor efficacy. Chem Eng J. 2024;494:153128.
49. Zheng J, Sun Y, Shen Y, Zhou Z. Surface engineering of nanoparticles for precision medicine. Precis Med Eng. 2025;2:100037.
50. Kay C, Martínez-Pérez C, Meehan J, et al. Current trends in the treatment of HR+/HER2+ breast cancer. Future Oncol. 2021;17:1665-81.
51. Huober J, Weder P, Veyret C, et al. PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207). Ann Oncol. 2018;29:viii93.
